Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma

Abstract

Spanish

French

Objective:

To evaluate the efficacy and safety of romidepsin in refractory cutaneous T-cell lymphoma (CTCL).

Data Sources:

An English-language literature search of PubMed and MEDLINE (Nov 2011–April 2012) was performed using the terms romidepsin, CTCL, and depsipeptide (FK228). The National Comprehensive Cancer Network guidelines, American Society of Clinical Oncology abstracts, American Society of Hematology abstracts, clinical trial registry, and prescribing information from the manufacturer were reviewed for additional information.

Study Selection and Data Extraction:

Phase 1 and 2 trials evaluating the efficacy and safety of romidepsin were reviewed with a specific focus on its use in cutaneous T-cell lymphoma. All peer-reviewed articles with clinically relevant information were evaluated for inclusion.

Data Synthesis:

In advanced stage CTCL, single or combination chemotherapy regimen responses are variable and lack durability. Romidepsin is a histone deacetylase inhibitor approved for refractory cutaneous T-cell lymphoma, Romidepsin has shown an improvement in duration of response and pruritus over traditional therapy. In 2 independent Phase 2 trials, romidepsin showed an overall response rate of 34% and durable response of 13–15 months in patients with refractory CTCL. The most frequent toxicities of romidepsin include nausea. vomiting, fatigue, or myelosuppresston. Clinically insignificant QT interval changes have been observed but did not correlate with a decrease in left ventricular ejection fraction, or elevated laboratory markers of myocardial damage.

Conclusions:

Romidepsin is an effective, durable, and well-tolerated single-agent therapy in patients with refractory CTCL and should be considered for formulary addition in this population.

Keywords

cutaneous T-cell lymphoma depepsitide (FK228)histone deacetylase inhibitor romidepsin

Get full access to this article

View all access options for this article.

References

Zinzani

, Ferreri

, Cerroni

. Mycosis fungoides. Crit Rev Oncol Hematol 2008; 65:172–82.

Criscione

, Weinstock

. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol 2007; 143:854–9.

Kim

, Liu

, Mraz-Gernhard

, Varghese

, Hoppe

. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139:857–66.

Bradford

, Devesa

, Anderson

, Toro

. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064–73.

Russell-Jones

, Whittaker

. Sézary syndrome: diagnostic criteria and therapeutic options. Semin Cutan Med Surg 2000; 19:100–8.

Poligone

, Lin

, Chung

. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid 2011; 6:1–12.

Whittaker

, Marsden

, Spittle

, Russell Jones

, Dermatologists BAo, Group UKCL. Joint British Association of Dermatologists and UK. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149:1095–107.

Trautinger

, Knobler

, Willemze

. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42:1014–30.

Wieselthier

, Koh

. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990; 22:381–401.

10.

Willemze

, Dreyling

, Group

EGW

. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5):v177–80.

11.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-Hodgkin's lymphoma. V.4.2011. www.nccn.org (accessed 2011 Dec 5).

12.

Gardner

, Evans

, Musiek

, Rook

, Kim

. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009; 21:131–7.

13.

Bunn

, Hoffman

, Norris

, Golitz

, Aeling

. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121:592–602.

14.

Piekarz

, Frye

, Turner

. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27:5410–7.

15.

Horwitz

. The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas. Curr Hematol Malig Rep 2011; 6:67–72.

16.

Bertino

, Otterson

. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011; 20:1151–8.

17.

Copeland

, Buglio

, Younes

. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010; 22:431–6.

18.

Yang

. Romidepsin: in the treatment of T-cell lymphoma. Drugs 2011; 71:1469–80.

19.

Jain

, Odenike

. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother 2010; 11:3073–84.

20.

Woo

, Gardner

, Chen

. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009; 15:1496–503.

21.

Product information. Istodax (romidepsin). Summit, NJ: Celgene Corporation, September 2011.

22.

Bates

, Zhan

, Steadman

. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010; 148:256–67.

23.

Sandor

, Bakke

, Robey

. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718–28.

24.

Marshall

, Rizvi

, Kauh

. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002; 2:325–32.

25.

Whittaker

, Demierre

, Kim

. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485–91.

26.

Olsen

, Kim

, Kuzel

. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109–15.

27.

Du vie

, Talpur

, Ni

. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31–9.

28.

Bunn

, Foon

, Ihde

. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101:484–7.

29.

Duvic

, Hymes

, Heald

. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456–71.

30.

Olsen

, Bunn

. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1089–107.

31.

Straus

, Duvic

, Kuzel

. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007; 109:1799–803.

32.

Olsen

, Duvic

, Frankel

. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376–88.

33.

Zic

. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16:337–46.

34.

Zic

, Stricklin

, Greer

. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35:935–45.

35.

Marchi

, Alinari

, Tani

. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104:2437–41.

36.

Zinzani

, Venturini

, Stefoni

. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010; 21:860–3.

37.

Pulini

, Rupoli

, Goteri

. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007; 92:686–9.

38.

Quereux

, Marques

, Nguyen

. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 2008; 144:727–33.

39.

Wollina

, Dummer

, Brockmeyer

. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98:993–1001.

40.

Horwitz

, Kim

, Foss

. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (abstract) Blood 2012; 119(18):4115–22.

41.

Zinzani

, Musuraca

, Tani

. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:4293–7.

42.

Akpek

, Koh

, Bogen

, O'Hara

, Foss

. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999; 86:1368–76.

43.

Lansigan

, Foss

. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70:273–86.

44.

Duarte

, Canals

, Onida

. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28:4492–9.

45.

Piekarz

, Sackett

, Bates

. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 2007; 13:30–9.

46.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis. V.I.2012. www.nccn.org (accessed 2012 Jan 20).

47.

Piekarz

, Frye

, Wright

. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12:3762–73.

48.

Hussar

, Christian

. New drugs: pitavastatin calcium, vigabatrin, and romidepsin. J Am Pharm Assoc (2003) 2010;50:548–51.

49.

Zain

, O'Connor

. Targeting histone deacetylases in the treatment of B- and T-cell malignancies. Invest New Drugs 2010; 28(suppl 1):S58–78.

50.

Newbold

, Lindemann

, Cluse

, Whitecross

, Dear

, Johnstone

. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008; 7:1066–79.

51.

Robey

, Chakraborty

, Basseville

. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm 2011; 8:2021–31.

52.

2010 Redbook. Montvale, NJ: Thompson Medical Economics, 2010.

53.

Piekarz

, Frye

, Prince

. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117:5827–34.

54.

Coiffier

, Pro

, Prince

. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral t-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30:631–6.